Hemostemix closes second tranche, raises CDN$322,250
- Investing.com
Metrics to compare | HEM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHEMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −2.3x | −0.3x | |
PEG Ratio | −1.06 | 0.01 | 0.00 | |
Price/Book | −2.6x | 0.5x | 2.6x | |
Price / LTM Sales | - | 2.6x | 3.0x | |
Upside (Analyst Target) | - | 32.1% | 54.6% | |
Fair Value Upside | Unlock | −4.0% | 8.6% | Unlock |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.